Peroxisome proliferator activated receptor-γ ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells
作者： Jiajun Liu , Huiling Lu , Renwei Huang , Dongjun Lin , Xiangyuan Wu
DOI: 10.1007/S00280-005-1029-9
关键词: Cancer research 、 Growth inhibition 、 Leukemia 、 Biology 、 K562 cells 、 Cell adhesion 、 Cell growth 、 Extracellular matrix 、 Myeloid leukemia 、 Matrigel
摘要: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is one of the best characterized nuclear hormone receptors (NHRs) in superfamily ligand-activated transcriptional factors. PPAR-gamma ligands have recently been demonstrated to affect proliferation, differentiation and apoptosis different cell types. The present study was undertaken investigate induced growth inhibition its influence on matrix metalloproteinase MMP-9 MMP-2 activities leukemia K562 HL-60 cells vitro. results revealed that expression detectable two kinds cells; Both 15-deoxy-delta(12,14)-prostaglandin J2(15d-PGJ2) troglitazone (TGZ) significant effects these cells. These could inhibit leukemic adhesion extracellular (ECM) proteins invasion through matrigel matrix. expressions as well their gelatinolytic both were inhibited by 15d-PGJ2 TGZ significantly. We therefore conclude myeloid vitro, can ECM downregulate expressions. data suggest may serve potential anti-leukemia reagents.
springer.com
sci-hub.se 参考文章(38)
Conor C. Lynch, Susan Mc Donnell, The role of matrilysin (MMP-7) in leukaemia cell invasion. Clinical & Experimental Metastasis. ,vol. 18, pp. 401- 406 ,(2000) , 10.1023/A:1010973808853
A. Margeli, G. Kouraklis, S. Theocharis, Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) Ligands and Angiogenesis Angiogenesis. ,vol. 6, pp. 165- 169 ,(2003) , 10.1023/B:AGEN.0000021377.13669.C0
H Sato, S Ishihara, K Kawashima, N Moriyama, H Suetsugu, H Kazumori, T Okuyama, M A K Rumi, R Fukuda, N Nagasue, Y Kinoshita, Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists British Journal of Cancer. ,vol. 83, pp. 1394- 1400 ,(2000) , 10.1054/BJOC.2000.1457
Dipak Panigrahy, Lucy Q Shen, Mark W Kieran, Arja Kaipainen, Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opinion on Investigational Drugs. ,vol. 12, pp. 1925- 1937 ,(2003) , 10.1517/13543784.12.12.1925
Xian-Ming Zhang, Shao-Peng Huang, Qiang Xu, Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway Cancer Chemotherapy and Pharmacology. ,vol. 53, pp. 82- 88 ,(2004) , 10.1007/S00280-003-0702-0
Eveline S. J. M. De Bont, Stefano Rosati, Susan Jacobs, Willem A. Kamps, Edo Vellenga, Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. British Journal of Haematology. ,vol. 113, pp. 296- 304 ,(2001) , 10.1046/J.1365-2141.2001.02722.X
Josué Padilla, Edmund Leung, Richard P. Phipps, Human B Lymphocytes and B Lymphomas Express PPAR-γ and Are Killed by PPAR-γ Agonists Clinical Immunology. ,vol. 103, pp. 22- 33 ,(2002) , 10.1006/CLIM.2001.5181
Toshihisa Hayashibara, Yasuaki Yamada, Yasuyuki Onimaru, Chizuko Tsutsumi, Susumu Nakayama, Naoki Mori, Takayuki Miyanishi, Shimeru Kamihira, Masao Tomonaga, Tetsuo Maita, Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion British Journal of Haematology. ,vol. 116, pp. 94- 102 ,(2002) , 10.1046/J.1365-2141.2002.03255.X
Yasuji Ueda, Takehiro Yamagishi, Kazunori Samata, Hisao Ikeya, Noriko Hirayama, Tadayasu Okazaki, Sumi Nishihara, Koshi Arai, Sachiko Yamaguchi, Masabumi Shibuya, Shiro Nakaike, Makoto Tanaka, A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth Cancer Chemotherapy and Pharmacology. ,vol. 54, pp. 16- 24 ,(2004) , 10.1007/S00280-004-0763-8
William G. Stetler-Stevenson, Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention Journal of Clinical Investigation. ,vol. 103, pp. 1237- 1241 ,(1999) , 10.1172/JCI6870